Summit Therapeutics rises after AstraZeneca commits $2B investment

Miami - AstraZeneca has committed $2 billion to Summit Therapeutics in the form of convertible preferred shares, along with embarking on clinical trial collaborations, according to a corporate announcement. The investment stems from the acquisition of approximately 108,955 shares of preferred stock, which will be converted into common stock at a 1:1,000 ratio, translating to a value of $18.36 per share.

This transaction is anticipated to be finalized by the end of the week, contingent upon standard conditions, as outlined in a press release.

Furthermore, the two companies have formed a clinical collaboration agreement to examine the efficacy of sonesitatug vedotin in conjunction with ivonescimab in addressing gastrointestinal cancers. Under this arrangement, each entity will contribute its respective compound, and they will share the costs of conducting the studies. While AstraZeneca will oversee the studies, both companies will preserve their development and commercial rights to their respective molecules.

In addition, Summit and AstraZeneca have signed a non-binding memorandum of understanding to explore the potential of conducting clinical trials that combine ivonescimab with various AstraZeneca cancer medicines, such as antibody drug conjugates. The collaboration encompasses no financial stipulations related to milestones, royalties, revenue-sharing, or profit-sharing.

Ivonescimab, an investigational bispecific antibody, was developed by Akeso Inc. (HKEX:9926) and is currently undergoing Phase III clinical trials. Summit submitted a Biologics License Application to the FDA for ivonescimab in January 2026, setting a provisional decision date of November 14, 2026. The application is predicated on findings from the HARMONi trial, which assessed ivonescimab's effectiveness in treating EGFR-mutated non-small cell lung cancer.

The memorandum of understanding remains non-binding, and there are no guarantees concerning the eventual execution of the clinical trial collaboration.